Microbot Medical Expands LIBERTY System Adoption to Pennsylvania, Now in Seven Eastern U.S. States
MBOT is trading near its 52-week low of $1.6 (10.0% above the low).
Summary
Microbot Medical announced the first adoption of its LIBERTY Endovascular Robotic System in Pennsylvania by a globally recognized academic center, expanding its presence to seven Eastern U.S. states.
Key Events · Product Development and Regulatory · MBOT
-
First Pennsylvania Adoption
A globally recognized academic center in Pennsylvania is the first in the state to adopt the LIBERTY Endovascular Robotic System.
-
Expanded Geographic Footprint
The company now has accounts in seven states across the Eastern U.S., with plans to expand its sales territory to the West Coast.
-
Continued Commercial Momentum
This adoption builds on recent positive commercial developments, including a full market release and a partnership to expand access to federal healthcare systems.
Analysis · MBOT · Industrial Applications And Services
Microbot Medical announced that a leading academic center in Pennsylvania has adopted its LIBERTY Endovascular Robotic System, marking the first such adoption in the state. This expands the company's commercial footprint to seven states across the Eastern U.S. and follows recent positive commercial momentum and a partnership to access federal healthcare systems. This indicates continued successful execution of its commercialization strategy and growing market acceptance for its robotic system.
At the time of this filing, MBOT was trading at $1.76 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $124.3M. The 52-week trading range was $1.60 to $4.67. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.